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Abstract 
Review on Primary Cutaneous CD8 Aggressive 
Epidermotropic Cytotoxic T Cell Lymphoma, with 
data on clinics, and the genes involved. 
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Disease 
Primary cutaneous CD8+ aggressive epidermotropic 
cytotoxic T cell lymphoma (AECTCL) had been 
considered a provisional disease until the 2016 
World Health Organization Classification of 
Cutaneous lymphomas (Guitart J et al, 2017). It is a 
rare cutaneous lymphoma, representing less than 1% 
of all cutaneous lymphomas and it has aggressive 
behavior and a poor prognosis (Willemze R et al, 
2005). 
Etiology 
AECTCL is a proliferation of epidermotropic CD8+ 
cytotoxic T cells with the expression oh TIA-1 
marker. 
Epidemiology 
AECTCL is rare, but most patients are adult with a 
median survival among 12 months (Berti E et al, 
1999). 
Clinics 
The clinical course usually begins with a prodrome 
of localized or disseminated eruptive papules, 
nodules, and tumors with a central 
ulceration/necrosis or hyperkeratotic 
patches/plaques in the skin and cutaneous adnexa. 
The disease rapidly disseminates to organs such as 
lungs, testis, CNS and oral mucosa in just weeks or 
months (Willemze R et al, 2008). Lymph nodes are 
not infiltrated by the disease. B symptoms (fever, 
night sweats, and weight loss) are seen in most 
patients. Some cases may be associated with 
hemophagocytic syndrome (Toro JR et al, 2003). 
Pathology 
Histologically the disease shows infiltrates of T cells 
in full epidermal thickness with a different degree of 
spongiosis, intraepidermal blistering and necrosis. In 
the early stages a lichenoid pattern with pagetoid 
epidermotropism and subepidermal edema is seen. 
In advances stages, diffuse dermal infiltrates in 
nodular and tumor-like lesions are characteristic. 
Epidermal necrosis and ulceration or destruction of 
skin structures are commonly found (Berti E et al, 
1999; Santucci M et al, 2003; Robson A e tal, 2015). 
The neoplastic cells showed a high Ki-67 
proliferation index.  
Immunophenotype AECTCL express a peripheral 
T cell phenotype with CD3+, CD8+, CD7+/-, 
CD45RA+, beta-F1+, Granzyme B+ (g-B), perforin 
(PF), T-intracytoplasmic antigen (TIA-1) and 
CD45RO-. CD2, CD4 and CD5 are frequently lost 
and CD30 is rarely expressed but they have a high 
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proliferation, expressed with Mib-1 marker. Epstein-
Barr virus is negative (Robson A et al, 2015; Guitart 
J et al, 2017; Quintanilla-Martinez L et al, 2013). 
AECTCL express clonal T cell receptor gene 
rearrangements. 
Genes 
The neoplastic T cells that are representative of this 
disease show clonal T cell receptor gene 
rearrangements. Specific genes abnormalities have 
not been described. 
Treatment 
Treatment remains unclear since no randomized 
trials are available. Peripheral T Cell lymphoma 
combination chemotherapy is usually tried but 
response rates remain poor (Berti E et al, 1999). 
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